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Canine Narcolepsy
by Steven E Roti, DVMt
Introduction
Narcolepsy is a disorder of the central
nervous system that is characterized by sud-
den, recurring attacks of sleep. Although nar-
colepsy was first described in the human med-
ical literature over ninety years ago, the first
case of canine narcolepsy was recognized in
1973. It currently has been reported in several
breeds of dogs, in cats, and in horses. It is a
well defined neurological condition in human
beings, afflicting as many as five to ten people
out of every 10,000. The major symptoms of
the disease in man are excessive daytime
sleepiness, cataplexy and, less often, sleep
paralysis and hypnogogic hallucinations.
Soon after Knecht et at first reported ca-
nine narcolepsy in 1973, Stanford University
acquired several dogs affected with the dis-
ease as models for the human disorder. 4 Since
then narcolepsy has been diagnosed in several
mixed and pure breeds of dogs.
Development of Narcolepsy
Features common to both human and ca-
nine narcolepsy are the development of sleep-
iness and cataplectic attacks early in life. Cat-
aplexy in the dog manifests itself as postural
collapse, areflexia, and partial to complete
muscle atony with a sparing of the respiratory
and occular muscles. 2 These symptoms
generally appear prior to six months of age in
the canine (over 75% showed symptoms by 6
months in a study conducted by Foutz et at).
No correlation between the age of onset of
cataplexy and the severity of the disorder has
been noted. Thus narcolepsy may develop
abruptly and undergo little change for the
rest of the patients life. It is interesting to note
that in man the symptoms of narcolepsy begin
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between 10-20 years of age in three out of
four of the cases. 9
Heritability
Narcolepsy is thought to be an inherited
trait, since the incidence of the disease in
related individuals is 200 times that of the
normal population. 2 In dogs, studies have
been carried out in a Stanford University col-
ony by mating narcoleptic Doberman Pins-
chers. Thus far, four litters have yielded 22
puppies, all of whom developed cataplexy.
However, the breeding of two narcoleptic
beagles has produced seven pups, all unaf-
fected. The debate continues as to whether
the disease is a polygenic or a single dominant
gene with low penetrance. Narcolepsy is defi-
nitely hereditary in some breeds, however it
may also be derived from developmental ac-
cidents or other nongenetic factors. 2
Symptoms of Narcolepsy
Sleepiness: Excessive somnolence is a
primary complaint among human narcoleptic
patients. These sleep attacks are sudden,
reversible, and last about 10 to 15 minutes.
Generally they occur while the patient is per-
forming in a boring situation. However, these
"sleep attacks" may occur under a variety of
situations, including driving, dancing, or
even swimming. 9
In most cases, somnolence does not signifi-
cantly affect the dog's behavior. Therefore
this is usually not a primary complaint or
presenting symptom by the owner. The most
common and most obvious clinical sign in the
dog is cataplexy.
Cataplexy: Cataplexy presents as an acute
attack of flaccid paralysis. These attacks are
frequently precipitated by the excitement of
such things as the presentation of food,
another dog, sexual activity, or sudden ap-
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pearance of their masters. Young puppies
seem more susceptible to attacks during
periods of playful activity. Cataplectic attacks
may last from a few seconds to several min-
utes. The dog will collapse in any position and
its eyes are open, alert, and following any
movement in the room. These attacks are
reversible by an external stimulus such as pet-
ting or calling the animal's name.
Sleep paralysis is reported in man to be an
inability to move or cry out and is often
associated with hypnogogic hallucinations
(i.e. a frightening or threatening dream).
Neither of these occurrences has been docu-
mented in the canine.
Normal Sleep Patterns in the Canine
It is believed that sleep in dogs, cats and in
humans occurs in three stages: nonrapid eye
movement (NREM), light slow-wave sleep
(LSWS), NREM deep slow-wave sleep
(DSWS), and rapid eye movement (REM)
sleep.3 Each of these stages can be
characterized by the presence or absence of
dreaming, muscle tone, and alternations in
the electroencephalogram (EEG). NREM
sleep is identified by the absence of REM, a
high voltage, slow activity EEG pattern, the
presence of muscle tone, and little or no
dreaming. REM sleep is characterized by
REM's, low voltage, fast activity EEG pattern,
an absence of muscle tone, and dreaming. 3,7
It is generally accepted that normal sleep pat-
terns consist of a period of NREMLSWS,
NREMDSWS, and REM sleep. In man, sleep
periods change from NREM to REM sleep
every 80 to 120 minutes. 3
Abnormal Sleep Patterns in the
Narcoleptic Canine
The dog afflicted with this disease
demonstrates altered normal sleep patterns.
These variations may manifest themselves as
excessive daytime sleepiness, disturbed night
time sleep, and abnormal REM sleep. It is im-
portant to note that the time spent sleeping
does not differ from normal but the duration
,and distribution of sleep phases are altered.3
Pathological REM sleep is observed clinically
in the dog by a sudden onset of sleep from an
alert state. The REM sleep in the canine is
characterized by closed eyelids, fascicular
twitches of the distal musculature, weak
vocalization, immobility, and a low voltage,
fast activity EEG pattern. 1 The usual period
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of NREM sleep is absent or at least greatly
reduced in time.
Etiology
The exact etiology of the narcoleptic syn-
drome has never been determined. Many
possible causes for narcolepsy have been pro-
posed in the human literature. Between 1920
and 1960, psychoanalysis developed many
theories emphasizing a psychogenic etiology.
Their theories proposed that feelings such as
sexual impulses, guilt feelings, hatred, etc.
were so unacceptable to the patient that the
narcoleptic sleep and cataplectic attacks serv-
ed as defense mechanisms for the repression
of such feelings. 9
Current investigations suggest the origins
for the disease may be in the area of the
reticular activating system. It is known that
REM sleep is initiated and regulated by areas
of the pontine reticular formation. Certain
areas here also initiate the muscle inhibition
and areflexia of REM sleep. NREM sleep is
thought to result from the inhibition of the
reticular activating system. 9 Some authorities
propose there is either an increased REM
discharge or a loss of the REM inhibition. Re-
cent theories suggest narcolepsy is a neuro-
transmitter problem. Current biochemical
analysis of cerebral spinal fluid in narcoleptic
dogs suggest reduced concentrations of
serotonin and dopamine and a decreased tur-
nover of norepinephrine. This suggests there
are low levels of neurotransmitters in the
brain of narcoleptics. Treatment of narcolep-
sy is aimed at increasing the concentration of
these neurotransmitters.
Diagnosis
The diagnosis of narcolepsy and catapiexy
is based primarily on the basis of history,
clinical signs, age of onset, and the exclusion
of other more common diseases. Foutz
described a food-elicited cataplexy test to
confirm the diagnosis of cataplexy in affected
dogs. 2 Ten one ml pieces of food are placed in
a row approximately 30 cm apart. The time
required to eat the food and the number of
attacks that occur is an index of severity.
Physostigmine salicylate (Antilirium), an an-
ticholinesterase, given intravenously at doses
ranging from .05 to 0.1 mg per kg greatly in-
creases the probability of a spontaneous at-
tack within 5 to 15 minutes after its injection.
An important differential that should be
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made is epilepsy. During cataplexy, no
urinary or fecal incontinence or excessive
salivation are seen. No tonic rigidity of the
musculature occurs with cataplexy either. It
should be noted that the nonepileptic will not
show improvement in response to anticon-
vulsants or barbiturates.
Another important differential is myas-
thenia gravis. Myasthenia can be ruled out if
the condition fails to imp:r.ove with peripheral
acting anticholinesterases such as neostig-
mine.
Hypokalemia may result in similar symp-
toms, however, the blood chemistry in nar-
coleptic dogs is within the normal range. Dif-
ferentials in human medicine also include
hypoglycemia and suspect hypothyroidism. 9
Treatment
Amphetamines, tricyclic antidepressants
and l\1AO inhibitors are the primary drugs
used in the treatment of the narcoleptic
humans. These drugs work Qy blocking the
re-uptake of CNS neurotransmitters, thereby
allowing their concentrations to increase at
the synaptic clefts, or by stopping excess or
normal enzymatic breakdown of neuro-
transmitters.
In narcoleptic humans, treatment is aim-
ed at control of excessive sleep and control of
cataplexy. Central nervous system stimulants
have been used in man to treat excessive
daytime sleepiness while tricyclic an-
tidepressants have been used to treat
cataplexy. 5
Controlling somnolence in dogs may not
be a high clinical priority since it usually fails
to significantly affect the animal's behavior.
Current drug therapy in the canine is aimed
at control of the cataplectic attacks. The
general stimulant methyphenidate hydro-
chloride (0.25 mg per kg) has marked anti-
cataplectic properties. It acts by suppressing
both REM and NREM sleep. 3 The tricyclic
antidepressant imipramine (Trofanil, 0.4 to
0.8 mg per kg) is used mQre commonly for
controlling cataplexy. It blocks the uptake of
serotonin and norepinephrine and suppresses
only REM sleep.
Another possibility for treatment that is
currently being investigated in dogs is the use
of monamine oxidase inhibitors. Their use in
man has been discontinued due to complica-
tions such as hypertension, edema, impotence
and severe cardiovascular side effects when
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the diet contained tyramine. 8.9
The clinician should not hope to com-
pletely block cataplexy but should attempt to
achieve .an acceptable reduction in frequency
and duration. It must be stressed that the
disease is not in itself life-threatening and that
it will not significantly get worse with time.
The owner should avoid exposing the animal
to situations that elicit unusual excitement
and to places where attacks may be dangerous
(e.g. busy streets). 2
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